Bloom the value of research and co-create a better future
3month2Today, Frost & SullivanxThe donation ceremony of the Frost & Sullivan China Partnership was successfully held in Shanghai. Dr. Wang Xin, Global Partner and President of the Greater China Region at Frost & Sullivan, Mao Hua, Partner and Managing Director of the Greater China Region at Frost & Sullivan, Wang Yigou, Founder and Vice Chairman of the Frost & Sullivan China Partnership, and Ma Tao, Secretary-General of the Frost & Sullivan China Partnership, along with their respective teams from both sides, attended the donation ceremony.
At the donation ceremony, Dr. Wang Xin, on behalf of Frost & SullivanFrost & SullivanFrost & Sullivan, referred to as 'Frost & Sullivan', has donated to the Beijing Pain Relief Challenge Public Welfare Foundation (referred to as 'Pain Relief Challenge Foundation', abbreviated as 'PRCF')ICF"") Donation10RMB 10,000,000 is earmarked to jointly advance the prevention and treatment of rare diseases in China, illuminating the light of life for patients with rare diseases.
As a globally renowned growth consulting firm, Frost & Sullivan has been focusing on its commitment to growth and its contribution to society for over six decades. Therefore, Frost & Sullivan has always regarded engaging in public welfare as an important part of its social responsibility.
Dr. Wang Xin, Global Partner and President of Frost & Sullivan Greater China, said: "Frost & Sullivan's corporate mission is to make the world a better place through growth. Corporate growth and social responsibility complement each other and are both the foundation of our existence. Since last year, Frost & Sullivan has partnered with the Foundation for Fighting Chronic Illnesses to provide public observation reports on the rare disease industry and to return the research income from these reports to the foundation to serve with knowledge. We hope to help more patients with rare diseases and also enable the capital market and investment institutions, as well as more businesses and individuals, to understand and pay attention to the field of rare diseases and this special group. Paying attention to the rare disease community is the responsibility of the whole society. This is a very meaningful thing and also a research topic that our company attaches great importance to, pays close attention to, and will invest in for a long time."
Wang Yike, founder and vice-chairman of the Pain Challenge Foundation, said: “ICFOur mission is to focus on patients, empower them, innovate, and connect relevant parties to jointly solve the urgent problems faced by the rare disease community. As a public welfare platform in the field of rare diseases,ICFWe have been collaborating with Frost & Sullivan on rare disease industry trend observation reports for two years. We aim to use the foundation's frontline service to patients, combined with Frost & Sullivan's expertise in industry analysis, to jointly document and present changes in the rare disease field. In the future,ICFWe look forward to continuing our collaboration with Frost & Sullivan to jointly address the urgent issues faced by the rare disease community, and at the same time To provide more valuable industry reports for partners from all walks of life dedicated to promoting the improvement of the living conditions of people with rare diseases. "
This year, both parties jointly released2023During the process of writing the 'China Rare Disease Industry Trend Observation Report', experts from the foundation provided comprehensive guidance for the report's compilation. Frost & Sullivan hopes that both parties will work together to transform the annual rare disease industry observation report into a high-level 'yearbook' of the rare disease industry, using their influence and platform resources to speak up for rare diseases.
In the future, Frost & Sullivan sincerely looks forward to working with all sectors to pay attention to and jointly safeguard this area, striving to help the rare disease community enjoy a colorful life. Frost & Sullivan will leverage its rich industry experience to assist in the development and maturation of the rare disease industry in China. Maintain long-term and in-depth cooperation with institutions such as the Foundation for the Challenge of Disease; continue to be committed to research in the field of rare diseases, actively fulfill our social responsibilities, and continuously contribute to helping 'Healthy China2030Contribute to construction.
